Skip to main content
Top
Published in: Critical Care 3/2009

Open Access 01-06-2009 | Research

Macrophage migration inhibitory factor in cerebrospinal fluid from patients with central nervous system infection

Authors: Christian Østergaard, Thomas Benfield

Published in: Critical Care | Issue 3/2009

Login to get access

Abstract

Introduction

Macrophage migration inhibitory factor (MIF) plays an essential pathophysiological role in septic shock, but its role in central nervous system infection (CNS) remains to be defined.

Methods

We investigated cerebrospinal fluid (CSF) levels of MIF in 171 patients who were clinically suspected of having meningitis on admission. Of these, 31 were found to have purulent meningitis of known aetiology, 20 purulent meningitis of unknown aetiology, 59 lymphocytic meningitis and 11 encephalitis, whereas 50 were suspected of having but had no evidence of CNS infection.

Results

CSF MIF levels were significantly higher in patients with purulent meningitis of known aetiology (median [interquartile range]: 8,639 [3,344 to 20,600] ng/l) than in patients with purulent meningitis of unknown aetiology (2,209 [1,516 to 6,550] ng/l; Mann-Whitney test, P = 0.003), patients with lymphocytic meningitis (1,912 [1,302 to 4,105] ng/l; P < 0.001) and patients suspected of having but without evidence of CNS infection (1,472 [672 to 3,447] ng/l; P < 0.001). Also, patients with encephalitis (6,937 [3,961 to 8,353] ng/l) had higher CSF MIF than did patients without CNS infection (P < 0.01). Among patients with purulent meningitis, CSF MIF levels were significantly higher in patients infected with pneumococci than in those with meningococcal infection (11,569 [8,615 to 21,935] ng/l versus 5,006 [1,717 to 10,905] ng/l; P = 0.02), in patients who required versus those not requiring assisted ventilation (10,493 [5,961 to 22,725] ng/l versus 3,240 [1,563 to 9,302] ng/l; P = 0.003), and in patients with versus those without impaired consciousness (8,614 [3,344 to 20,935] ng/l versus 2,625 [1,561 to 7,530] ng/l; P = 0.02). CSF MIF levels correlated significantly with meningeal inflammation (P < 0.05) but not with systemic inflammatory response (P > 0.05) in patients with purulent meningitis of known aetiology, those with lymphocytic meningitis and those with encephalitis.

Conclusions

MIF was significantly increased in the CSF of patients with purulent meningitis and encephalitis, and was to some degree associated with severity of the infection. Our findings indicate that MIF may play an important role in CNS infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Morand EF: New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 2005, 35: 419-426. 10.1111/j.1445-5994.2005.00853.xCrossRefPubMed Morand EF: New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 2005, 35: 419-426. 10.1111/j.1445-5994.2005.00853.xCrossRefPubMed
2.
go back to reference Renner P, Roger T, Calandra T: Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 2005, 41: S513-S519. 10.1086/432009CrossRefPubMed Renner P, Roger T, Calandra T: Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 2005, 41: S513-S519. 10.1086/432009CrossRefPubMed
3.
go back to reference Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6: 164-170. 10.1038/72262CrossRefPubMed Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6: 164-170. 10.1038/72262CrossRefPubMed
4.
go back to reference Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004, 22: 309-313. 10.1097/01.shk.0000140305.01641.c8CrossRefPubMed Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004, 22: 309-313. 10.1097/01.shk.0000140305.01641.c8CrossRefPubMed
5.
go back to reference Emonts M, Sweep FC, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, Erard V, Renner P, Hermans PW, Hazelzet JA, Calandra T: Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007, 44: 1321-1328. 10.1086/514344CrossRefPubMed Emonts M, Sweep FC, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, Erard V, Renner P, Hermans PW, Hazelzet JA, Calandra T: Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007, 44: 1321-1328. 10.1086/514344CrossRefPubMed
6.
go back to reference Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365: 756-759. 10.1038/365756a0CrossRefPubMed Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365: 756-759. 10.1038/365756a0CrossRefPubMed
7.
go back to reference Scheld WM, Koedel U, Nathan B, Pfister HW: Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis 2002,186(suppl 2):S225-S233. 10.1086/344939CrossRefPubMed Scheld WM, Koedel U, Nathan B, Pfister HW: Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis 2002,186(suppl 2):S225-S233. 10.1086/344939CrossRefPubMed
8.
go back to reference de Gans J, Beek D: Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002, 347: 1549-1556. 10.1056/NEJMoa021334CrossRefPubMed de Gans J, Beek D: Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002, 347: 1549-1556. 10.1056/NEJMoa021334CrossRefPubMed
9.
go back to reference Østergaard C, Benfield TL, Sellebjerg F, Kronborg G, Lohse N, Lundgren JD: Interleukin-8 in cerebrospinal fluid from patients with septic and aseptic meningitis. Eur J Clin Microbiol Infect Dis 1996, 15: 166-169. 10.1007/BF01591492CrossRefPubMed Østergaard C, Benfield TL, Sellebjerg F, Kronborg G, Lohse N, Lundgren JD: Interleukin-8 in cerebrospinal fluid from patients with septic and aseptic meningitis. Eur J Clin Microbiol Infect Dis 1996, 15: 166-169. 10.1007/BF01591492CrossRefPubMed
10.
go back to reference Østergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD: YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol 2002, 9: 598-604.PubMedCentralPubMed Østergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD: YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol 2002, 9: 598-604.PubMedCentralPubMed
11.
go back to reference Østergaard C, Benfield T, Lundgren JD, Eugen-Olsen J: Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004, 36: 14-19. 10.1080/00365540310017366CrossRefPubMed Østergaard C, Benfield T, Lundgren JD, Eugen-Olsen J: Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004, 36: 14-19. 10.1080/00365540310017366CrossRefPubMed
12.
go back to reference Kastenbauer S, Angele B, Sporer B, Pfister HW, Koedel U: Patterns of protein expression in infectious meningitis: a cerebrospinal fluid protein array analysis. J Neuroimmunol 2005, 164: 134-139. 10.1016/j.jneuroim.2005.03.009CrossRefPubMed Kastenbauer S, Angele B, Sporer B, Pfister HW, Koedel U: Patterns of protein expression in infectious meningitis: a cerebrospinal fluid protein array analysis. J Neuroimmunol 2005, 164: 134-139. 10.1016/j.jneuroim.2005.03.009CrossRefPubMed
13.
go back to reference Arjona A, Foellmer HG, Town T, Leng L, McDonald C, Wang T, Wong SJ, Montgomery RR, Fikrig E, Bucala R: Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 2007, 117: 3059-3066. 10.1172/JCI32218PubMedCentralCrossRefPubMed Arjona A, Foellmer HG, Town T, Leng L, McDonald C, Wang T, Wong SJ, Montgomery RR, Fikrig E, Bucala R: Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 2007, 117: 3059-3066. 10.1172/JCI32218PubMedCentralCrossRefPubMed
14.
go back to reference Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J: Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000, 179: 127-131. 10.1016/S0022-510X(00)00397-XCrossRefPubMed Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J: Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000, 179: 127-131. 10.1016/S0022-510X(00)00397-XCrossRefPubMed
15.
go back to reference Popp J, Bacher M, Kolsch H, Noelker C, Deuster O, Dodel R, Jessen F: Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2009, 43: 749-753. 10.1016/j.jpsychires.2008.10.006CrossRefPubMed Popp J, Bacher M, Kolsch H, Noelker C, Deuster O, Dodel R, Jessen F: Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2009, 43: 749-753. 10.1016/j.jpsychires.2008.10.006CrossRefPubMed
16.
go back to reference Powell ND, Papenfuss TL, McClain MA, Gienapp IE, Shawler TM, Satoskar AR, Whitacre CC: Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J Immunol 2005, 175: 5611-5614.CrossRefPubMed Powell ND, Papenfuss TL, McClain MA, Gienapp IE, Shawler TM, Satoskar AR, Whitacre CC: Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J Immunol 2005, 175: 5611-5614.CrossRefPubMed
17.
go back to reference Denkinger CM, Denkinger M, Kort JJ, Metz C, Forsthuber TG: In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003, 170: 1274-1282.CrossRefPubMed Denkinger CM, Denkinger M, Kort JJ, Metz C, Forsthuber TG: In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003, 170: 1274-1282.CrossRefPubMed
18.
go back to reference Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179: 1895-1902. 10.1084/jem.179.6.1895CrossRefPubMed Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179: 1895-1902. 10.1084/jem.179.6.1895CrossRefPubMed
19.
go back to reference Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996, 93: 7849-7854. 10.1073/pnas.93.15.7849PubMedCentralCrossRefPubMed Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996, 93: 7849-7854. 10.1073/pnas.93.15.7849PubMedCentralCrossRefPubMed
20.
go back to reference Borregaard N, Cowland JB: Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997, 89: 3503-3521.PubMed Borregaard N, Cowland JB: Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997, 89: 3503-3521.PubMed
21.
go back to reference Hagberg L: The clinical use of cerebrospinal fluid neopterin in central nervous system infections. Pteridines 1996, 6: 147-152. Hagberg L: The clinical use of cerebrospinal fluid neopterin in central nervous system infections. Pteridines 1996, 6: 147-152.
22.
go back to reference Clark IA, Awburn MM, Whitten RO, Harper CG, Liomba NG, Molyneux ME, Taylor TE: Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. Malar J 2003, 2: 6. 10.1186/1475-2875-2-6PubMedCentralCrossRefPubMed Clark IA, Awburn MM, Whitten RO, Harper CG, Liomba NG, Molyneux ME, Taylor TE: Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. Malar J 2003, 2: 6. 10.1186/1475-2875-2-6PubMedCentralCrossRefPubMed
23.
go back to reference Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377: 68-71. 10.1038/377068a0CrossRefPubMed Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377: 68-71. 10.1038/377068a0CrossRefPubMed
24.
go back to reference Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, Meinhardt A, Bucala R: Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 2003, 162: 47-56.PubMedCentralCrossRefPubMed Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, Meinhardt A, Bucala R: Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 2003, 162: 47-56.PubMedCentralCrossRefPubMed
25.
go back to reference Ichiyama H, Onodera S, Nishihira J, Ishibashi T, Nakayama T, Minami A, Yasuda K, Tohyama H: Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 2004, 26: 187-194. 10.1016/j.cyto.2004.02.007CrossRefPubMed Ichiyama H, Onodera S, Nishihira J, Ishibashi T, Nakayama T, Minami A, Yasuda K, Tohyama H: Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 2004, 26: 187-194. 10.1016/j.cyto.2004.02.007CrossRefPubMed
26.
go back to reference Mikulowska A, Metz CN, Bucala R, Holmdahl R: Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997, 158: 5514-5517.PubMed Mikulowska A, Metz CN, Bucala R, Holmdahl R: Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997, 158: 5514-5517.PubMed
27.
go back to reference de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Alsahli M, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK, Terhorst C: Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001, 2: 1061-1066. 10.1038/ni720CrossRefPubMed de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Alsahli M, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK, Terhorst C: Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001, 2: 1061-1066. 10.1038/ni720CrossRefPubMed
28.
go back to reference Nakajima H, Takagi H, Horiguchi N, Toyoda M, Kanda D, Otsuka T, Emoto Y, Emoto M, Mori M: Lack of macrophage migration inhibitory factor protects mice against concanavalin A-induced liver injury. Liver Int 2006, 26: 346-351. 10.1111/j.1478-3231.2005.01216.xCrossRefPubMed Nakajima H, Takagi H, Horiguchi N, Toyoda M, Kanda D, Otsuka T, Emoto Y, Emoto M, Mori M: Lack of macrophage migration inhibitory factor protects mice against concanavalin A-induced liver injury. Liver Int 2006, 26: 346-351. 10.1111/j.1478-3231.2005.01216.xCrossRefPubMed
29.
go back to reference Lan HY, Bacher M, Yang N, Mu W, Nikolic-Paterson DJ, Metz C, Meinhardt A, Bucala R, Atkins RC: The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997, 185: 1455-1465. 10.1084/jem.185.8.1455PubMedCentralCrossRefPubMed Lan HY, Bacher M, Yang N, Mu W, Nikolic-Paterson DJ, Metz C, Meinhardt A, Bucala R, Atkins RC: The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997, 185: 1455-1465. 10.1084/jem.185.8.1455PubMedCentralCrossRefPubMed
30.
go back to reference Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, Zhang Y, Satoskar AR, David JR, Metz CN, Bucala R, Fang K, Simon DI, Chapman HA, Libby P, Shi GP: Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2004, 109: 3149-3153. 10.1161/01.CIR.0000134704.84454.D2CrossRefPubMed Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, Zhang Y, Satoskar AR, David JR, Metz CN, Bucala R, Fang K, Simon DI, Chapman HA, Libby P, Shi GP: Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2004, 109: 3149-3153. 10.1161/01.CIR.0000134704.84454.D2CrossRefPubMed
31.
go back to reference Brandt CT, Lundgren JD, Lund SP, Frimodt-Møller N, Christensen T, Espersen F, Hovgaard D, Østergaard C: Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis. Infect Immun 2004, 72: 4647-4653. 10.1128/IAI.72.8.4647-4653.2004PubMedCentralCrossRefPubMed Brandt CT, Lundgren JD, Lund SP, Frimodt-Møller N, Christensen T, Espersen F, Hovgaard D, Østergaard C: Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis. Infect Immun 2004, 72: 4647-4653. 10.1128/IAI.72.8.4647-4653.2004PubMedCentralCrossRefPubMed
Metadata
Title
Macrophage migration inhibitory factor in cerebrospinal fluid from patients with central nervous system infection
Authors
Christian Østergaard
Thomas Benfield
Publication date
01-06-2009
Publisher
BioMed Central
Published in
Critical Care / Issue 3/2009
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc7933

Other articles of this Issue 3/2009

Critical Care 3/2009 Go to the issue